Selcia United Kingdom

Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling.

Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated.  USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.

Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.

Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.

Areas of Expertise:

• Medicinal chemistry:  Tool compounds; peptides; macrocycles; natural product chemistry

• Biology: Assay development

• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology

• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions

• 14C Custom Radiosynthesis

• GMP 14C Radiolabelled API for Clinical Trials

• GLP/GMP Analytics – GLP NMR

• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds

contact@selcia.com

Organisation type
Mr Dave Roberts
BD Director, Radiochemistry 
Dr Vicky Steadman
Director, Discovery 

Syne qua non United Kingdom

Exhibiting at booth 89a

Syne qua non Limited (SQN) is one of the world’s recognised specialist clinical biometrics CROs supporting global pharma, biotech, medical device and animal health partners with innovative clinical development services.  SQN was previously honoured with a Queen’s Award for Enterprise in 2009, in the international trade category in recognition of our business growth and export performance. We are extremely proud to have won the 2017 Queen’s Award for Innovation for Syne-clin, our innovative EDC and Trial Management system.

Utilising standard validated library elements to build each study system, Syne-clin delivers significant time and cost savings and shortens the drug development cycle, accelerating the process of getting new medical treatments to market. Incorporating mobile, tablet and smartphone device data collection, Syne-clin allows real-time collection of patient clinical outcomes utilising electronic diary and questionnaire functionality.

Our technology and innovation project has also allowed SQN to successfully compete internationally and win clinical research projects from overseas competition thus supporting and enhancing the reputation of the UK as a centre of excellence for pharmaceutical and healthcare research. This trend continues as the rapid and ongoing development of mobile and wearable devices creates opportunities to collect patient data in ways previously not possible. Our technology incorporates these developments and allows enhanced functionality and added value, this will allow us to continue to increase market share and generate new business opportunities.

For a demo of the system come and see us at Stand 89A

Organisation type
Mr Tony Rees
Director 
Mrs Karen Grover
Director 

SYNthesis med chem United Kingdom

SYNthesis med chem is a chemistry-focussed contract research organisation that carries out custom synthesis, medicinal chemistry and integrated drug discovery projects for biotech & pharma companies and research institutes. In addition to providing chemistry services, SYNthesis also establishes shared risk collaborations with partners, the goal being to identify, develop and partner small molecule drugs.

Organisation type
Prof Andrew Wilks
Chairman 
Mr Simon Bury
Global Head of Business Development 

Tepnel Pharma Services United Kingdom

We focus on the provision of pharmaceutical testing in support of drug development with an emphasis on inhalation, oral dosage, parenteral and biologics. Our people are committed to providing laboratory services that deliver on the promise of quality, through a highly skilled workforce and a customer focused performance working alongside you towards a common goal. Our cGMP pharmaceutical testing facility is located in Livingston, Scotland where we work together with our customers and partners building mutual trust through a sharing of knowledge, expertise and teamwork.

Organisation type
Ms Ponchi Kantt-Neaz
Business Development Manager 

Ubiquigent United Kingdom

Ubiquigent provides its partners with unparalleled access to the technologies, skills and expertise required to support drug discovery in the ubiquitin field. The ubiquitin system offers many new drug discovery target opportunities across multiple therapeutic areas including cancer, cardiovascular and metabolic, neurological and musculoskeletal, and infection and immunity. 

To support the exploitation of the ubiquitin system Ubiquigent has launched the first novel compound library designed to target Deubiquitylase (DUB) enzymes (DUBtarget-001), with further compound libraries now in development. Ubiquigent also provides access to specialist drug discovery services, high quality research tools and chemistry to support groups that are either already active in or wish to enter this exciting new field. 

The ubiquitin system is based on the modification of proteins through the attachment of the protein ubiquitin, or ubiquitin-like proteins (Ubls). Ubiquitylation and related Ubl modifications are key to the control of cellular protein homeostasis as well as signalling, akin to the critical role played by phosphorylation (approximately 30% of commercial drug discovery programmes target phosphorylation enzymes), and holds similar if not greater potential for clinical utility.

Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery. Ubiquigent benefits from high calibre backing including from IP Group plc, US investors, the UK Medical Research Council, and the University of Dundee. The company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.

Organisation type
Mr Jason Mundin
Commercial Director 

United Life Sciences United Kingdom

United Life Sciences (ULS) is a strategic partnership representing over 1240 life science and healthcare organisations across the UK and internationally. The partnership was formed by four Founding Partners: the BioIndustry Association (BIA), Bionow, BioPartner UK and One Nucleus (ON) in 2014 and MediWales joined in 2015

The ULS collaboration has member and the wider UK life science sector at the heart of its purpose and is the basis for all joint activities. We strive to avoid duplication of effort and coordinate the founders' activities whilst recognising each other's areas of strength so that member companies can benefit from more effective and coherent sector support.

Since 2012 ULS partners have worked together on a range of activities - including the creation and publication of a UK Life Science Manifesto 2015 - 2020 which was aimed at all political parties, and called for the Biomedical Catalyst scheme to be continued in the interest of the nation's health and wealth

ULS has also hosted a number of joint events both in the UK and overseas, and will be undertaking further joint initiatives plus providing cost effective attendance at each other's events to maximise the international impact of the UK. Discounts are available to each other's members for 3 of each of our major events so please check with your membership organisation for details.

Dr Geoff Davison
Bionow 
Ms Lin Bateson
BioPartner UK 
Mr Michael McGivern
UK BioIndustry Association 
Mrs Aline Charpentier
One Nucleus 
Mr Gywn Tudor
MediWales 
Dr Tony Jones
One Nucleus 
Ms Alex Whicher
UK BioIndustry Association